Novel regulators of airway epithelial barrier function during inflammation: potential targets for drug repurposing

References

• Bustamante-Marin XM, Ostrowski LE. Cilia and Mucociliary Clearance. Cold Spring Harb Perspect Biol. 2017 Apr 3;9(4):a028241.
   PubMed Web of Science ®Google Scholar
• Rock JR, Randell SH, Hogan BL. Airway basal stem cells: a perspective on their roles in epithelial homeostasis and remodeling. Dis Model Mech. 2010 Oct;3(9–10):545–556.
   PubMed Web of Science ®Google Scholar
• Crystal RG, Randell SH, Engelhardt JF, et al. Airway epithelial cells: current concepts and challenges. Proc Am Thorac Soc. 2008 Sep 15;5(7):772–777.
   PubMedGoogle Scholar
• Saunders CJ, Reynolds SD, Finger TE. Chemosensory brush cells of the trachea. A stable population in a dynamic epithelium. Am J Respir Cell Mol Biol. 2013 Aug;49(2):190–196.
   PubMed Web of Science ®Google Scholar
• Mogensen C, Tos M. Quantitative histology of the maxillary sinus. Rhinology. 1977 Sep;15(3):129–140.
   PubMedGoogle Scholar
• Round AN, Rigby NM, Garcia de la Torre A, et al. Lamellar structures of MUC2-rich mucin: a potential role in governing the barrier and lubricating functions of intestinal mucus. Biomacromolecules. 2012 Oct 8;13(10):3253–3261.
   PubMed Web of Science ®Google Scholar
• Whitsett JA. Airway epithelial differentiation and mucociliary clearance. Ann Am Thorac Soc. 2018 Nov;15(3):143–148.
   Google Scholar
• Boers JE, Ambergen AW, Thunnissen FB. Number and proliferation of clara cells in normal human airway epithelium. Am J Respir Crit Care Med. 1999 May;159(5 Pt 1):1585–1591.
   PubMed Web of Science ®Google Scholar
• Rawlins EL, Okubo T, Xue Y, et al. The role of Scgb1a1+ Clara cells in the long-term maintenance and repair of lung airway, but not alveolar, epithelium. Cell Stem Cell. 2009 Jun 5;4(6):525–534.
   PubMed Web of Science ®Google Scholar
• Rokicki W, Rokicki M, Wojtacha J, et al. The role and importance of club cells (Clara cells) in the pathogenesis of some respiratory diseases. Kardiochir Torakochirurgia Pol. 2016 Mar;13(1):26–30.
   PubMedGoogle Scholar
• Zuo WL, Shenoy SA, Li S, et al. Ontogeny and biology of human small airway epithelial club cells. Am J Respir Crit Care Med. 2018 Dec 1;198(11):1375–1388.
   PubMed Web of Science ®Google Scholar
• Reynolds SD, Malkinson AM. Clara cell: progenitor for the bronchiolar epithelium. Int J Biochem Cell Biol. 2010 Jan;42(1):1–4.
   PubMed Web of Science ®Google Scholar
• Parimon T, Yao C, Stripp BR, et al. Alveolar epithelial type ii cells as drivers of lung fibrosis in idiopathic pulmonary fibrosis. Int J Mol Sci. 2020 Mar 25;21(7):2269.
   PubMed Web of Science ®Google Scholar
• Ritter A, Kreis NN, Louwen F, et al. Obesity and COVID-19: molecular mechanisms linking both pandemics. Int J Mol Sci. 2020 Aug 12;21(16):5793.
   Web of Science ®Google Scholar
• Knight DA, Holgate ST. The airway epithelium: structural and functional properties in health and disease. Respirology. 2003 Dec;8(4):432–446.
   PubMed Web of Science ®Google Scholar
• Amatngalim GD, Hiemstra PS. Airway epithelial cell function and respiratory host defense in chronic obstructive pulmonary disease. Chin Med J (Engl). 2018 May 5;131(9):1099–1107.
   PubMed Web of Science ®Google Scholar
• Tatsuta M, Kan-O K, Ishii Y, et al. Effects of cigarette smoke on barrier function and tight junction proteins in the bronchial epithelium: protective role of cathelicidin LL-37. Respir Res. 2019 Nov 9;20(1):251.
   PubMed Web of Science ®Google Scholar
• Kojima T, Murata M, Go M, et al. Connexins induce and maintain tight junctions in epithelial cells. J Membr Biol. 2007 Jun;217(1–3):13–19.
   PubMed Web of Science ®Google Scholar
• Brune K, Frank J, Schwingshackl A, et al. Pulmonary epithelial barrier function: some new players and mechanisms. Am J Physiol Lung Cell Mol Physiol. 2015 Apr 15;308(8):L731–45.
   PubMed Web of Science ®Google Scholar
• Singh B, Coffey RJ. Trafficking of epidermal growth factor receptor ligands in polarized epithelial cells. Annu Rev Physiol. 2014;76:275–300.
   PubMed Web of Science ®Google Scholar
• Zieske JD, Takahashi H, Hutcheon AE, et al. Activation of epidermal growth factor receptor during corneal epithelial migration. Invest Ophthalmol Vis Sci. 2000 May;41(6):1346–1355.
   PubMed Web of Science ®Google Scholar
• Lambrecht BN, Hammad H. The airway epithelium in asthma. Nat Med. 2012 May 4;18(5):684–692.
   PubMed Web of Science ®Google Scholar
• Stanke F. The contribution of the airway epithelial cell to host defense. Mediators Inflamm. 2015;2015;463016.
   PubMed Web of Science ®Google Scholar
• Stanke F, Becker T, Cuppens H, et al. The TNFalpha receptor TNFRSF1A and genes encoding the amiloride-sensitive sodium channel ENaC as modulators in cystic fibrosis. Hum Genet. 2006 Apr;119(3):331–343.
   PubMed Web of Science ®Google Scholar
• Guillot L, Nathan N, Tabary O, et al. Alveolar epithelial cells: master regulators of lung homeostasis. Int J Biochem Cell Biol. 2013 Nov;45(11):2568–2573.
   PubMed Web of Science ®Google Scholar
• Mortaz E, Adcock IM, Tabarsi P, et al. Interaction of pattern recognition receptors with mycobacterium tuberculosis. J Clin Immunol. 2015 Jan;35(1):1–10.
   PubMed Web of Science ®Google Scholar
• Månsson Kvarnhammar A, Tengroth L, Adner M, et al. Innate immune receptors in human airway smooth muscle cells: activation by TLR1/2, TLR3, TLR4, TLR7 and NOD1 agonists. PLoS One. 2013 Jul 4;8(7):e68701.
   PubMed Web of Science ®Google Scholar
• Heijink IH, Kuchibhotla VNS, Roffel MP, et al. Epithelial cell dysfunction, a major driver of asthma development. Allergy. 2020 Aug;75(8):1902–1917.
   PubMed Web of Science ®Google Scholar
• Lee TH, Song HJ, Park CS. Role of inflammasome activation in development and exacerbation of asthma. Asia Pac Allergy. 2014 Oct;4(4):187–196.
   PubMedGoogle Scholar
• Gras D, Chanez P, Vachier I, et al. Bronchial epithelium as a target for innovative treatments in asthma. Pharmacol Ther. 2013 Dec;140(3):290–305.
   PubMed Web of Science ®Google Scholar
• Stanke F, Becker T, Kumar V, et al. Genes that determine immunology and inflammation modify the basic defect of impaired ion conductance in cystic fibrosis epithelia. J Med Genet. 2011 Jan;48(1):24–31.
   PubMed Web of Science ®Google Scholar
• Jiang XQ, Mei XD, Feng D. Air pollution and chronic airway diseases: what should people know and do? J Thorac Dis. 2016 Jan;8(1):E31–40.
   PubMed Web of Science ®Google Scholar
• Tam A, Wadsworth S, Dorscheid D, et al. The airway epithelium: more than just a structural barrier. Ther Adv Respir Dis. 2011 Aug;5(4):255–273.
   PubMedGoogle Scholar
• Boxall C, Holgate ST, Davies DE. The contribution of transforming growth factor-beta and epidermal growth factor signalling to airway remodelling in chronic asthma. Eur Respir J. 2006 Jan;27(1):208–229.
   PubMed Web of Science ®Google Scholar
• Beckett PA, Howarth PH. Pharmacotherapy and airway remodelling in asthma? Thorax. 2003 Feb;58(2):163–174.
   PubMed Web of Science ®Google Scholar
• Paw M, Wnuk D, Jakieła B, et al. Responsiveness of human bronchial fibroblasts and epithelial cells from asthmatic and non-asthmatic donors to the transforming growth factor-β1 in epithelial-mesenchymal trophic unit model. BMC Mol Cell Biol. 2021 Mar 12;22(1):19.
   PubMed Web of Science ®Google Scholar
• Bergeron C, Tulic MK, Hamid Q. Airway remodelling in asthma: from benchside to clinical practice. Can Respir J. 2010 Aug;17(4):e85–93.
   PubMed Web of Science ®Google Scholar
• Chakir J, Laviolette M, Boutet M, et al. Lower airways remodeling in nonasthmatic subjects with allergic rhinitis. Lab Invest. 1996 Nov;75(5):735–744.
   PubMed Web of Science ®Google Scholar
• Chu HW, Halliday JL, Martin RJ, et al. Collagen deposition in large airways may not differentiate severe asthma from milder forms of the disease. Am J Respir Crit Care Med. 1998 Dec;158(6):1936–1944.
   PubMed Web of Science ®Google Scholar
• Wenzel SE, Schwartz LB, Langmack EL, et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med. 1999 Sep;160(3):1001–1008.
   PubMed Web of Science ®Google Scholar
• Bayfield KJ, Douglas TA, Rosenow T, et al. Time to get serious about the detection and monitoring of early lung disease in cystic fibrosis. Thorax. 2021Apr29; 76(12)1255–1265. thoraxjnl-2020-216085
   PubMed Web of Science ®Google Scholar
• Samarin S, Nusrat A. Regulation of epithelial apical junctional complex by Rho family GTPases. Front Biosci (Landmark Ed). 2009 Jan 1;14:1129–1142.
   PubMed Web of Science ®Google Scholar
• Shen L, Weber CR, Raleigh DR, et al. Tight junction pore and leak pathways: a dynamic duo. Annu Rev Physiol. 2011;73:283–309.
   PubMed Web of Science ®Google Scholar
• Schneeberger EE, Lynch RD. The tight junction: a multifunctional complex. Am J Physiol Cell Physiol. 2004 Jun;286(6):C1213–28.
   PubMed Web of Science ®Google Scholar
• Georas SN, Rezaee F. Epithelial barrier function: at the front line of asthma immunology and allergic airway inflammation. J Allergy Clin Immunol. 2014 Sep;3(134):509–520.
   Google Scholar
• Wong JF, Simmons CA. Microfluidic assay for the on-chip electrochemical measurement of cell monolayer permeability. Lab Chip. 2019 Mar 13;19(6):1060–1070.
   PubMed Web of Science ®Google Scholar
• Furuse M. Molecular basis of the core structure of tight junctions. Cold Spring Harb Perspect Biol. 2010 Jan;2(1):a002907.
   PubMed Web of Science ®Google Scholar
• Inai T, Kamimura T, Hirose E, et al. The protoplasmic or exoplasmic face association of tight junction particles cannot predict paracellular permeability or heterotypic claudin compatibility. Eur J Cell Biol. 2010 Jul;89(7):547–556.
   PubMed Web of Science ®Google Scholar
• Furuse M, Fujita K, Hiiragi T, et al. Claudin-1 and −2: novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin. J Cell Biol. 1998 Jun 29;141(7):1539–1550.
   PubMed Web of Science ®Google Scholar
• Raleigh DR, Marchiando AM, Zhang Y, et al. Tight junction-associated MARVEL proteins marveld3, tricellulin, and occludin have distinct but overlapping functions. Mol Biol Cell. 2010 Apr 1;21(7):1200–1213.
   PubMed Web of Science ®Google Scholar
• Wawrzyniak P, Wawrzyniak M, Wanke K, et al. Regulation of bronchial epithelial barrier integrity by type 2 cytokines and histone deacetylases in asthmatic patients. J Allergy Clin Immunol. 2017 Jan;139(1):93–103.
   PubMed Web of Science ®Google Scholar
• Saitou M, Furuse M, Sasaki H, et al. Complex phenotype of mice lacking occludin, a component of tight junction strands. Mol Biol Cell. 2000 Dec;11(12):4131–4142.
   PubMed Web of Science ®Google Scholar
• Sakakibara A, Furuse M, Saitou M, et al. Possible involvement of phosphorylation of occludin in tight junction formation. J Cell Biol. 1997 Jun 16;137(6):1393–1401.
   PubMed Web of Science ®Google Scholar
• Ramezanpour M, Moraitis S, Smith JL, et al. Th17 cytokines disrupt the airway mucosal barrier in chronic rhinosinusitis. Mediators Inflamm. 2016;2016:9798206.
   PubMed Web of Science ®Google Scholar
• Huber D, Balda MS, Matter K. Occludin modulates transepithelial migration of neutrophils. J Biol Chem. 2000Feb25;275(8):5773–5778.
   PubMed Web of Science ®Google Scholar
• Edelblum KL, Shen L, Weber CR, et al. Dynamic migration of γδ intraepithelial lymphocytes requires occludin. Proc Natl Acad Sci U S A. 2012 May 1;109(18):7097–7102.
   PubMed Web of Science ®Google Scholar
• Walters RW, Freimuth P, Moninger TO, et al. Adenovirus fiber disrupts CAR-mediated intercellular adhesion allowing virus escape. Cell. 2002 Sep 20;110(6):789–799.
   PubMed Web of Science ®Google Scholar
• Monteiro AC, Sumagin R, Rankin CR, et al. JAM-A associates with ZO-2, afadin, and PDZ-GEF1 to activate Rap2c and regulate epithelial barrier function. Mol Biol Cell. 2013 Sep;24(18):2849–2860.
   PubMed Web of Science ®Google Scholar
• Lakshmi SP, Reddy AT, Naik MU, et al. Effects of JAM-A deficiency or blocking antibodies on neutrophil migration and lung injury in a murine model of ALI. Am J Physiol Lung Cell Mol Physiol. 2012 Nov 1;303(9):L758–66.
   PubMed Web of Science ®Google Scholar
• Hernández-Martínez R, Ramkumar N, Anderson KV. p120-catenin regulates WNT signaling and EMT in the mouse embryo. Proc Natl Acad Sci U S A. 2019 Aug 20;116(34):16872–16881.
   PubMed Web of Science ®Google Scholar
• Lan H, Luo L, Chen Y, et al. MIF signaling blocking alleviates airway inflammation and airway epithelial barrier disruption in a HDM-induced asthma model. Cell Immunol. 2020 Jan;347:103965.
   PubMed Web of Science ®Google Scholar
• Türkeli A, Yilmaz Ö, Karaman M, et al. Anti-VEGF treatment suppresses remodeling factors and restores epithelial barrier function through the E-cadherin/β-catenin signaling axis in experimental asthma models. Exp Ther Med. 2021 Jul;22(1):689.
   PubMed Web of Science ®Google Scholar
• Niessen CM. Tight junctions/adherens junctions: basic structure and function. J Invest Dermatol. 2007 Nov;127(11):2525–2532.
   PubMed Web of Science ®Google Scholar
• Yamada S, Pokutta S, Drees F, et al. Deconstructing the cadherin-catenin-actin complex. Cell. 2005 Dec 2;123(5):889–901.
   PubMed Web of Science ®Google Scholar
• Laitinen A, Laitinen LA. Airway morphology: epithelium/basement membrane. Am J Respir Crit Care Med. 1994 Nov;150(5 Pt 2):S14–7.
   PubMed Web of Science ®Google Scholar
• Paulsson M. Basement membrane proteins: structure, assembly, and cellular interactions. Crit Rev Biochem Mol Biol. 1992;27(1–2):93–127.
   PubMed Web of Science ®Google Scholar
• Elliot JG, Noble PB, Mauad T, et al. Inflammation-dependent and independent airway remodelling in asthma. Respirology. 2018 Dec;23(12):1138–1145.
   PubMed Web of Science ®Google Scholar
• Siddiqui MT, Garrity ER, Martinez R, et al. Bronchiolar basement membrane changes associated with bronchiolitis obliterans in lung allografts: a retrospective study of serial transbronchial biopsies with immunohistochemistry [corrected]. Mod Pathol. 1996 Mar;9(3):320–328.
   PubMedGoogle Scholar
• Shaw JO. Leukocytes in chemotactic-fragment-induced lung inflammation. Vascular emigration and alveolar surface migration. Am J Pathol. 1980 Nov;101(2):283–302.
   PubMed Web of Science ®Google Scholar
• Koval M, Ward C, Findley MK, et al. Extracellular matrix influences alveolar epithelial claudin expression and barrier function. Am J Respir Cell Mol Biol. 2010 Feb;42(2):172–180.
   PubMed Web of Science ®Google Scholar
• Saatian B, Rezaee F, Desando S, et al. Interleukin-4 and interleukin-13 cause barrier dysfunction in human airway epithelial cells. Tissue Barriers. 2013 Apr 1;1(2):e24333.
   PubMedGoogle Scholar
• Ricciardolo FLM, Bertolini F, Carriero V. The role of dupilumab in severe asthma. Biomedicines. 2021 Aug 27;9(9):1096.
   PubMed Web of Science ®Google Scholar
• Wenzel S, Ford L, Pearlman D, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013 Jun 27;368(26):2455–2466.
   PubMed Web of Science ®Google Scholar
• Wenzel S, Castro M, Corren J, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016 Jul 2;388(10039):31–44.
   PubMed Web of Science ®Google Scholar
• Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018 Jun 28;378(26):2486–2496.
   PubMed Web of Science ®Google Scholar
• Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018 Jun 28;378(26):2475–2485.
   PubMed Web of Science ®Google Scholar
• Dupin C, Belhadi D, Guilleminault L, et al. Effectiveness and safety of dupilumab for the treatment of severe asthma in a real-life French multi-centre adult cohort. Clin Exp Allergy. 2020 Jul;50(7):789–798.
   PubMed Web of Science ®Google Scholar
• Maspero JF, Katelaris CH, Busse WW, et al. dupilumab efficacy in uncontrolled, moderate-to-severe asthma with self-reported chronic rhinosinusitis. J Allergy Clin Immunol Pract. 2020 Feb;8(2):527–539.e9.
   PubMed Web of Science ®Google Scholar
• Oeser K, Schwartz C, Voehringer D. Conditional IL-4/IL-13-deficient mice reveal a critical role of innate immune cells for protective immunity against gastrointestinal helminths. Mucosal Immunol. 2015 May;8(3):672–682.
   PubMed Web of Science ®Google Scholar
• Negrão-Corrêa D, Pinho V, Souza DG, et al. Expression of IL-4 receptor on non-bone marrow-derived cells is necessary for the timely elimination of Strongyloides venezuelensis in mice, but not for intestinal IL-4 production. Int J Parasitol. 2006 Sep;36(10–11):1185–1195.
   PubMed Web of Science ®Google Scholar
• Hofmann U, Knorr S, Vogel B, et al. Interleukin-13 deficiency aggravates healing and remodeling in male mice after experimental myocardial infarction. Circ Heart Fail. 2014 Sep;7(5):822–830.
   PubMed Web of Science ®Google Scholar
• Ingram N, Northwood EL, Perry SL, et al. Reduced type II interleukin-4 receptor signalling drives initiation, but not progression, of colorectal carcinogenesis: evidence from transgenic mouse models and human case-control epidemiological observations. Carcinogenesis. 2013 Oct;34(10):2341–2349.
   PubMed Web of Science ®Google Scholar
• Steelant B, Wawrzyniak P, Martens K, et al. Blocking histone deacetylase activity as a novel target for epithelial barrier defects in patients with allergic rhinitis. J Allergy Clin Immunol. 2019 Nov;144(5):1242–1253.e7.
   PubMed Web of Science ®Google Scholar
• Beckers T, Burkhardt C, Wieland H, et al. Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group. Int J Cancer. 2007 Sep 1;121(5):1138–1148.
   PubMed Web of Science ®Google Scholar
• Khan N, Jeffers M, Kumar S, et al. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J. 2008 Jan 15;409(2):581–589.
   PubMed Web of Science ®Google Scholar
• Yang SR, Chida AS, Bauter MR, et al. Cigarette smoke induces proinflammatory cytokine release by activation of NF-kappaB and posttranslational modifications of histone deacetylase in macrophages. Am J Physiol Lung Cell Mol Physiol. 2006 Jul;291(1):L46–57.
   PubMed Web of Science ®Google Scholar
• Nguyen TTT, Zhang Y, Shang E, et al. HDAC inhibitors elicit metabolic reprogramming by targeting super-enhancers in glioblastoma models. J Clin Invest. 2020 Jul 1;130(7):3699–3716.
   PubMed Web of Science ®Google Scholar
• Afaloniati H, Angelopoulou K, Giakoustidis A, et al. HDAC1/2 inhibitor romidepsin suppresses DEN-Induced hepatocellular carcinogenesis in mice. Onco Targets Ther. 2020 Jun 15;13:5575–5588.
   PubMed Web of Science ®Google Scholar
• Phiel CJ, Zhang F, Huang EY, et al. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem. 2001 Sep 28;276(39):36734–36741.
   PubMed Web of Science ®Google Scholar
• Richon VM, Emiliani S, Verdin E, et al. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):3003–3007.
   PubMed Web of Science ®Google Scholar
• Hutt DM, Herman D, Rodrigues AP, et al. Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis. Nat Chem Biol. 2010 Jan;6(1):25–33.
   PubMed Web of Science ®Google Scholar
• Li Y, Zhao K, Yao C, et al. Givinostat, a type II histone deacetylase inhibitor, induces potent caspase-dependent apoptosis in human lymphoblastic leukemia. Genes Cancer. 2016 Sep;7(9–10):292–300.
   PubMedGoogle Scholar
• Fournel M, Bonfils C, Hou Y, et al. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Mol Cancer Ther. 2008 Apr;7(4):759–768.
   PubMed Web of Science ®Google Scholar
• Zhou N, Moradei O, Raeppel S, et al. Discovery of N-(2-aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino)methyl]benzamide (MGCD0103), an orally active histone deacetylase inhibitor. J Med Chem. 2008 Jul 24;51(14):4072–4075.
   PubMed Web of Science ®Google Scholar
• Buggy JJ, Cao ZA, Bass KE, et al. CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo. Mol Cancer Ther. 2006 May;5(5):1309–1317.
   PubMed Web of Science ®Google Scholar
• Zhang S, Gong Z, Oladimeji PO, et al. A high-throughput screening identifies histone deacetylase inhibitors as therapeutic agents against medulloblastoma. Exp Hematol Oncol. 2019 Nov 15;8:30.
   PubMed Web of Science ®Google Scholar
• Wang Y, Wallach J, Duane S, et al. Developing selective histone deacetylases (HDACs) inhibitors through ebselen and analogs. Drug Des Devel Ther. 2017 May 2;11:1369–1382.
   PubMed Web of Science ®Google Scholar
• Saito A, Yamashita T, Mariko Y, et al. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4592–4597.
   PubMed Web of Science ®Google Scholar
• Glaser KB, Li J, Pease LJ, et al. Differential protein acetylation induced by novel histone deacetylase inhibitors. Biochem Biophys Res Commun. 2004 Dec 17;325(3):683–690.
   PubMed Web of Science ®Google Scholar
• Hsu CW, Shou D, Huang R, et al. Identification of HDAC inhibitors using a cell-based HDAC I/II Assay. J Biomol Screen. 2016 Jul;21(6):643–652.
   PubMedGoogle Scholar
• Ganai SA. Histone deacetylase inhibitor pracinostat in doublet therapy: a unique strategy to improve therapeutic efficacy and to tackle herculean cancer chemoresistance. Pharm Biol. 2016 Sep;54(9):1926–1935.
   PubMed Web of Science ®Google Scholar
• Butler LM, Webb Y, Agus DB, et al. Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase. Clin Cancer Res. 2001 Apr;7(4):962–970.
   PubMed Web of Science ®Google Scholar
• Venugopal B, Baird R, Kristeleit RS, et al. A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumors. Clin Cancer Res. 2013 Aug 1;19(15):4262–4272.
   PubMed Web of Science ®Google Scholar
• Napper AD, Hixon J, McDonagh T, et al. Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1. J Med Chem. 2005 Dec 15;48(25):8045–8054.
   PubMed Web of Science ®Google Scholar
• Undevia SD, Kindler HL, Janisch L, et al. A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine. Ann Oncol. 2004 Nov;15(11):1705–1711.
   PubMed Web of Science ®Google Scholar
• Pauer LR, Olivares J, Cunningham C, et al. Phase I study of oral CI-994 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors. Cancer Invest. 2004;22(6):886–896.
   PubMed Web of Science ®Google Scholar
• Ning ZQ, Li ZB, Newman MJ, et al. Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity. Cancer Chemother Pharmacol. 2012 Apr;69(4):901–909.
   PubMed Web of Science ®Google Scholar
• Novotny-Diermayr V, Sangthongpitag K, Hu CY, et al. SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer. Mol Cancer Ther. 2010 Mar;9(3):642–652.
   PubMed Web of Science ®Google Scholar
• Carol H, Gorlick R, Kolb EA, et al. Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the pediatric preclinical testing program. Pediatr Blood Cancer. 2014 Feb;61(2):245–252.
   PubMed Web of Science ®Google Scholar
• Lu B, Wang C, Wang M, et al. Molecular mechanism and therapeutic modulation of high mobility group box 1 release and action: an updated review. Expert Rev Clin Immunol. 2014 Jun;10(6):713–727.
   PubMed Web of Science ®Google Scholar
• Ferhani N, Letuve S, Kozhich A, et al. Expression of high-mobility group box 1 and of receptor for advanced glycation end products in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010 May 1;181(9):917–927.
   PubMed Web of Science ®Google Scholar
• Hou C, Zhao H, Liu L, et al. High mobility group protein B1 (HMGB1) in asthma: comparison of patients with chronic obstructive pulmonary disease and healthy controls. Mol Med. 2011;17(7–8):807–815.
   PubMed Web of Science ®Google Scholar
• Heijink IH, Pouwels SD, Leijendekker C, et al. Cigarette smoke-induced damage-associated molecular pattern release from necrotic neutrophils triggers proinflammatory mediator release. Am J Respir Cell Mol Biol. 2015 May;52(5):554–562.
   PubMed Web of Science ®Google Scholar
• Huang W, Zhao H, Dong H, et al. High-mobility group box 1 impairs airway epithelial barrier function through the activation of the RAGE/ERK pathway. Int J Mol Med. 2016 May;37(5):1189–1198.
   PubMed Web of Science ®Google Scholar
• Horiuchi T, Sakata N, Narumi Y, et al. Metformin directly binds the alarmin HMGB1 and inhibits its proinflammatory activity. J Biol Chem. 2017 May 19;292(20):8436–8446.
   PubMed Web of Science ®Google Scholar
• Tsoyi K, Jang HJ, Nizamutdinova IT, et al. Metformin inhibits HMGB1 release in LPS-treated RAW 264.7 cells and increases survival rate of endotoxaemic mice. Br J Pharmacol. 2011 Apr;162(7):1498–1508.
   PubMed Web of Science ®Google Scholar
• Eustace BK, Sakurai T, Stewart JK, et al. Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness. Nat Cell Biol. 2004 Jun;6(6):507–514.
   PubMed Web of Science ®Google Scholar
• Sims JD, McCready J, Jay DG. Extracellular heat shock protein (Hsp)70 and Hsp90α assist in matrix metalloproteinase-2 activation and breast cancer cell migration and invasion. PLoS One. 2011 Apr 14;6(4):e18848.
   PubMed Web of Science ®Google Scholar
• Ye C, Huang C, Zou M, et al. The role of secreted Hsp90α in HDM-induced asthmatic airway epithelial barrier dysfunction. BMC Pulm Med. 2019 Nov 20;19(1):218.
   PubMed Web of Science ®Google Scholar
• Ying W, Du Z, Sun L, et al. Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy. Mol Cancer Ther. 2012 Feb;11(2):475–484.
   PubMed Web of Science ®Google Scholar
• Hu Y, Bobb D, He J, et al. The HSP90 inhibitor alvespimycin enhances the potency of telomerase inhibition by imetelstat in human osteosarcoma. Cancer Biol Ther. 2015;16(6):949–957.
   PubMed Web of Science ®Google Scholar
• Whitesell L, Mimnaugh EG, De Costa B, et al. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci U S A. 1994 Aug 30;91(18):8324–8328.
   PubMed Web of Science ®Google Scholar
• Schneider C, Sepp-Lorenzino L, Nimmesgern E, et al. Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90. Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14536–14541.
   PubMed Web of Science ®Google Scholar
• Eccles SA, Massey A, Raynaud FI, et al. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res. 2008 Apr 15;68(8):2850–2860.
   PubMed Web of Science ®Google Scholar
• Stingl L, Stühmer T, Chatterjee M, et al. Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction. Br J Cancer. 2010 May 25;102(11):1578–1591.
   PubMed Web of Science ®Google Scholar
• Spiegelberg D, Abramenkovs A, Mortensen ACL, et al. The HSP90 inhibitor Onalespib exerts synergistic anti-cancer effects when combined with radiotherapy: an in vitro and in vivo approach. Sci Rep. 2020 Apr 3;10(1):5923.
   PubMed Web of Science ®Google Scholar
• Wagner AJ, Chugh R, Rosen LS, et al. A phase I study of the HSP90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft-tissue sarcomas. Clin Cancer Res. 2013 Nov 1;19(21):6020–6029.
   PubMed Web of Science ®Google Scholar
• Schulte TW, Neckers LM. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharmacol. 1998;42(4):273–279.
   PubMed Web of Science ®Google Scholar
• Rahmani M, Reese E, Dai Y, et al. Cotreatment with suberanoylanilide hydroxamic acid and 17-allylamino 17-demethoxygeldanamycin synergistically induces apoptosis in Bcr-Abl+ Cells sensitive and resistant to STI571 (imatinib mesylate) in association with down-regulation of Bcr-Abl, abrogation of signal transducer and activator of transcription 5 activity, and Bax conformational change. Mol Pharmacol. 2005 Apr;67(4):1166–1176.
   PubMed Web of Science ®Google Scholar
• Bullens DM, Decraene A, Dilissen E, et al. Type III IFN-lambda mRNA expression in sputum of adult and school-aged asthmatics. Clin Exp Allergy. 2008 Sep;38(9):1459–1467.
   PubMed Web of Science ®Google Scholar
• Major J, Crotta S, Llorian M, et al. Type I and III interferons disrupt lung epithelial repair during recovery from viral infection. Science. 2020 Aug 7;369(6504):712–717.
   PubMed Web of Science ®Google Scholar
• Channappanavar R, Fehr AR, Zheng J, et al. IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes. J Clin Invest. 2019 Jul 29;2129(9):3625–3639.
   Google Scholar
• Frieman MB, Chen J, Morrison TE, et al. SARS-CoV pathogenesis is regulated by a STAT1 dependent but a type I, II and III interferon receptor independent mechanism. PLoS Pathog. 2010 Apr 8;6(4):1000849.
   Web of Science ®Google Scholar
• da Silva J, Hilzendeger C, Moermans C, et al. Raised interferon-β, type 3 interferon and interferon-stimulated genes - evidence of innate immune activation in neutrophilic asthma. Clin Exp Allergy. 2017 Mar;47(3):313–323.
   PubMed Web of Science ®Google Scholar
• Broggi A, Ghosh S, Sposito B, et al. Type III interferons disrupt the lung epithelial barrier upon viral recognition. Science. 2020 Aug 7;369(6504):706–712.
   PubMed Web of Science ®Google Scholar
• Contoli M, Message SD, Laza-Stanca V, et al. Role of deficient type III interferon-lambda production in asthma exacerbations. Nat Med. 2006 Sep;12(9):1023–1026.
   PubMed Web of Science ®Google Scholar
• Zhu J, Message SD, Mallia P, et al. Bronchial mucosal IFN-α/β and pattern recognition receptor expression in patients with experimental rhinovirus-induced asthma exacerbations. J Allergy Clin Immunol. 2019 Jan;143(1):114–125.e4.
   PubMed Web of Science ®Google Scholar
• Sykes A, Edwards MR, Macintyre J, et al. Rhinovirus 16-induced IFN-α and IFN-β are deficient in bronchoalveolar lavage cells in asthmatic patients. J Allergy Clin Immunol. 2012 Jun;129(6):1506–1514.e6.
   PubMed Web of Science ®Google Scholar
• Rich HE, Antos D, Melton NR, et al. Insights Into Type I and III Interferons in Asthma and Exacerbations. Front Immunol. 2020 Sep 25;11:574027.
   PubMed Web of Science ®Google Scholar
• Bastard P, Rosen LB, Zhang Q, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020 Oct 23;370(6515):eabd4585.
   PubMed Web of Science ®Google Scholar
• Bastard P, Gervais A, Le Voyer T, et al. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Sci Immunol. 2021 Aug 19;6(62):eabl4340.
   PubMed Web of Science ®Google Scholar
• Lan H, Wang N, Chen Y, et al. Macrophage migration inhibitory factor (MIF) promotes rat airway muscle cell proliferation and migration mediated by ERK1/2 and FAK signaling. Cell Biol Int. 2018 Jan;42(1):75–83.
   PubMed Web of Science ®Google Scholar
• Calandra T, Bernhagen J, Metz CN, et al. MIF as a glucocorticoid-induced modulator of cytokine production. Nature. 1995 Sep 7;377(6544):68–71.
   PubMed Web of Science ®Google Scholar
• Trivedi-Parmar V, Jorgensen WL. Advances and insights for small molecule inhibition of macrophage migration inhibitory factor. J Med Chem. 2018 Sep 27;61(18):8104–8119.
   PubMed Web of Science ®Google Scholar
• Bloom J, Metz C, Nalawade S, et al. Identification of iguratimod as an inhibitor of macrophage migration inhibitory factor (MIF) with steroid-sparing potential. J Biol Chem. 2016 Dec 16;291(51):26502–26514.
   PubMed Web of Science ®Google Scholar
• Mahalingam D, Patel MR, Sachdev JC, et al. Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours. Br J Clin Pharmacol. 2020 Sep;86(9):1836–1848.
   PubMed Web of Science ®Google Scholar
• Hu Y, Lou J, Mao YY, et al. Activation of MTOR in pulmonary epithelium promotes LPS-induced acute lung injury. Autophagy. 2016 Dec;12(12):2286–2299.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Jing Y, Qiao J, et al. Activation of the mTOR signaling pathway is required for asthma onset. Sci Rep. 2017 Jul 3;7(1):4532. cytokine balance in mouse asthma model
   PubMedGoogle Scholar
• Allen SA, Tomilov A, Cortopassi GA. Small molecules bind human mTOR protein and inhibit mTORC1 specifically. Biochem Pharmacol. 2018 Sep;155:298–304.
   PubMed Web of Science ®Google Scholar
• Helal MG, Said E. Carvedilol attenuates experimentally induced silicosis in rats via modulation of P-AKT/mTOR/TGFβ1 signaling. Int Immunopharmacol. 2019 May;70:47–55.
   PubMed Web of Science ®Google Scholar
• Mensah FA, Blaize JP, Bryan LJ. Spotlight on copanlisib and its potential in the treatment of relapsed/refractory follicular lymphoma: evidence to date. Onco Targets Ther. 2018 Aug 13;11:4817–4827.
   PubMed Web of Science ®Google Scholar
• Homicsko K, Lukashev A, Iggo RD. RAD001 (everolimus) improves the efficacy of replicating adenoviruses that target colon cancer. Cancer Res. 2005 Aug 1;65(15):6882–6890.
   PubMed Web of Science ®Google Scholar
• Nazim UM, Moon JH, Lee YJ, et al. Glipizide sensitizes lung cancer cells to TRAIL-induced apoptosis via Akt/mTOR/autophagy pathways. Oncotarget. 2017 Oct 9;8(59):100021–100033.
   PubMedGoogle Scholar
• Sandoval JA, Tomilov A, Datta S, et al. Novel mTORC1 inhibitors kill glioblastoma stem cells. Pharmaceuticals (Basel). 2020 Nov 24;13(12):419.
   Google Scholar
• Khanfar MA, AbuKhader MM, Alqtaishat S, et al. Pharmacophore modeling, homology modeling, and in silico screening reveal mammalian target of rapamycin inhibitory activities for sotalol, glyburide, metipranolol, sulfamethizole, glipizide, and pioglitazone. J Mol Graph Model. 2013 May;42:39–49.
   PubMed Web of Science ®Google Scholar
• San YZ, Liu Y, Zhang Y, et al. Peroxisome proliferator-activated receptor-γ agonist inhibits the mammalian target of rapamycin signaling pathway and has a protective effect in a rat model of status epilepticus. Mol Med Rep. 2015 Aug;12(2):1877–1883.
   PubMed Web of Science ®Google Scholar
• Easton JB, Houghton PJ. mTOR and cancer therapy. Oncogene. 2006 Oct 16;25(48):6436–6446.
   PubMed Web of Science ®Google Scholar
• Wan X, Shen N, Mendoza A, et al. CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/VEGF signaling. Neoplasia. 2006 May;8(5):394–401.
   PubMed Web of Science ®Google Scholar
• Powles T, Lackner MR, Oudard S, et al. randomized open-label phase II trial of apitolisib (GDC-0980), a novel inhibitor of the PI3K/mammalian target of rapamycin pathway, versus everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol. 2016 May 10;34(14):1660–1668.
   PubMed Web of Science ®Google Scholar
• Shi F, Zhang J, Liu H, et al. The dual PI3K/mTOR inhibitor dactolisib elicits anti-tumor activity in vitro and in vivo. Oncotarget. 2017 Dec 9;9(1):706–717.
   PubMedGoogle Scholar
• Lukey PT, Harrison SA, Yang S, et al. A randomised, placebo-controlled study of omipalisib (PI3K/mTOR) in idiopathic pulmonary fibrosis. Eur Respir J. 2019 Mar 18;53(3):1801992.
   PubMed Web of Science ®Google Scholar
• Folkes AJ, Ahmadi K, Alderton WK, et al. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J Med Chem. 2008 Sep 25;51(18):5522–5532.
   PubMed Web of Science ®Google Scholar
• Mita MM, Mita A, Rowinsky EK. Mammalian target of rapamycin: a new molecular target for breast cancer. Clin Breast Cancer. 2003 Jun;4(2):126–137.
   PubMedGoogle Scholar
• Panwalkar A, Verstovsek S, Giles FJ. Mammalian target of rapamycin inhibition as therapy for hematologic malignancies. Cancer. 2004 Feb 15;100(4):657–666.
   PubMed Web of Science ®Google Scholar
• Voss MH, Gordon MS, Mita M, et al. Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer. Br J Cancer. 2020 Nov;123(11):1590–1598.
   PubMed Web of Science ®Google Scholar
• Te Fong AC W, Thavasu P, Gagrica S, et al. Evaluation of the combination of the dual m-TORC1/2 inhibitor vistusertib (AZD2014) and paclitaxel in ovarian cancer models. Oncotarget. 2017 Dec 6;8(69):113874–113884.
   PubMedGoogle Scholar
• Iwamoto H, Gao J, Koskela J, et al. Differences in plasma and sputum biomarkers between COPD and COPD-asthma overlap. Eur Respir J. 2014 Feb;43(2):421–429.
   PubMed Web of Science ®Google Scholar
• Wang Y, Jia M, Yan X, et al. Increased neutrophil gelatinase-associated lipocalin (NGAL) promotes airway remodelling in chronic obstructive pulmonary disease. Clin Sci (Lond). 2017 May 22;131(11):1147–1159.
   PubMed Web of Science ®Google Scholar
• Hynes GM, Hinks TSC. The role of interleukin-17 in asthma: a protective response? ERJ Open Res. 2020 May 26;6(2):00364–2019.
   PubMedGoogle Scholar
• Busse WW, Holgate S, Kerwin E, et al. Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. Am J Respir Crit Care Med. 2013 Dec 1;188(11):1294–1302.
   PubMed Web of Science ®Google Scholar
• Eich A, Urban V, Jutel M, et al. A Randomized, Placebo-Controlled Phase 2 Trial of CNTO 6785 in Chronic Obstructive Pulmonary Disease. COPD. 2017 Oct;14(5):476–483.
   PubMedGoogle Scholar
• Staton TL, Peng K, Owen R, et al. A phase I, randomized, observer-blinded, single and multiple ascending-dose study to investigate the safety, pharmacokinetics, and immunogenicity of BITS7201A, a bispecific antibody targeting IL-13 and IL-17, in healthy volunteers. BMC Pulm Med. 2019 Jan 7;19(1):5.
   PubMedGoogle Scholar
• Soyka MB, Wawrzyniak P, Eiwegger T, et al. Defective epithelial barrier in chronic rhinosinusitis: the regulation of tight junctions by IFN-γ and IL-4. J Allergy Clin Immunol. 2012 Nov;130(5):1087–1096.e10.
   PubMed Web of Science ®Google Scholar
• Saeki H, Nakagawa H, Nakajo K, et al. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: results from a 52-week, open-label, phase 3 study (UNCOVER-J). J Dermatol. 2017 Apr;44(4):355–362.
   PubMed Web of Science ®Google Scholar
• Dubash S, Bridgewood C, McGonagle D, et al. The advent of IL-17A blockade in ankylosing spondylitis: secukinumab, ixekizumab and beyond. Expert Rev Clin Immunol. 2019 Feb;15(2):123–134.
   PubMed Web of Science ®Google Scholar
• Foulkes AC, Warren RB. Brodalumab in psoriasis: evidence to date and clinical potential. Drugs Context. 2019 Apr 17;8:212570.
   PubMedGoogle Scholar
• Lee CG, Ma B, Takyar S, et al. Studies of vascular endothelial growth factor in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2011 Nov;8(6):512–515.
   PubMedGoogle Scholar
• Hoshino M, Takahashi M, Aoike N. Expression of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin immunoreactivity in asthmatic airways and its relationship to angiogenesis. J Allergy Clin Immunol. 2001 Feb;107(2):295–301.
   PubMed Web of Science ®Google Scholar
• Ludinsky M, Christner S, Su N, et al. The effects of VEGF-A-inhibitors aflibercept and ranibizumab on the ciliary body and iris of monkeys. Graefes Arch Clin Exp Ophthalmol. 2016 Jun;254(6):1117–1125.
   PubMed Web of Science ®Google Scholar
• Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun. 2005 Jul 29;333(2):328–335.
   PubMed Web of Science ®Google Scholar
• Ghosh AK. Regulation by prostaglandin E2 and histamine of angiogenesis in inflammatory granulation tissue. Yakugaku Zasshi. 2003 May;123(5):295–303.
   PubMed Web of Science ®Google Scholar
• Tangkeangsirisin W, Hayashi J, Serrero G. PC cell-derived growth factor mediates tamoxifen resistance and promotes tumor growth of human breast cancer cells. Cancer Res. 2004 Mar 1;64(5):1737–1743.
   PubMed Web of Science ®Google Scholar
• Gaudreault J, Fei D, Rusit J, et al. Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci. 2005 Feb;46(2):726–733.
   PubMed Web of Science ®Google Scholar
• Tsuji F, Seki I, Aono H, et al. Bucillamine mechanism inhibiting IL-1beta-induced VEGF production from fibroblast-like synoviocytes. Int Immunopharmacol. 2007 Dec 5;7(12):1569–1576.
   PubMed Web of Science ®Google Scholar
• Cochran S, Li C, Fairweather JK, et al. Probing the interactions of phosphosulfomannans with angiogenic growth factors by surface plasmon resonance. J Med Chem. 2003 Oct 9;46(21):4601–4608.
   PubMed Web of Science ®Google Scholar
• Cassinelli G, Zuco V, Petrangolini G, et al. The curative efficacy of namitecan (ST1968) in preclinical models of pediatric sarcoma is associated with antiangiogenic effects. Biochem Pharmacol. 2012 Jul 15;84(2):163–171.
   PubMed Web of Science ®Google Scholar
• Ng EW, Shima DT, Calias P, et al. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov. 2006 Feb;5(2):123–132.
   PubMed Web of Science ®Google Scholar
• Yoshida M, Tokuda H, Ishisaki A, et al. Tiludronate inhibits prostaglandin F2alpha-induced vascular endothelial growth factor synthesis in osteoblasts. Mol Cell Endocrinol. 2005 May 31;236(1–2):59–66.
   PubMed Web of Science ®Google Scholar
• Hu-Lowe DD, Zou HY, Grazzini ML, et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res. 2008 Nov 15;14(22):7272–7283.
   PubMed Web of Science ®Google Scholar
• Hilberg F, Roth GJ, Krssak M, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 2008 Jun 15;68(12):4774–4782.
   PubMed Web of Science ®Google Scholar
• Kumar R, Knick VB, Rudolph SK, et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther. 2007 Jul;6(7):2012–2021.
   PubMed Web of Science ®Google Scholar
• Wilhelm S, Carter C, Lynch M, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov. 2006 Oct;5(10):835–844.
   PubMed Web of Science ®Google Scholar
• Yuasa T, Takahashi S, Hatake K, et al. Biomarkers to predict response to sunitinib therapy and prognosis in metastatic renal cell cancer. Cancer Sci. 2011 Nov;102(11):1949–1957.
   PubMed Web of Science ®Google Scholar
• Nakamura K, Taguchi E, Miura T, et al. KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties. Cancer Res. 2006 Sep 15;66(18):9134–9142.
   PubMed Web of Science ®Google Scholar
• Choy DF, Modrek B, Abbas AR, et al. Gene expression patterns of Th2 inflammation and intercellular communication in asthmatic airways. J Immunol. 2011 Feb 1;186(3):1861–1869.
   PubMed Web of Science ®Google Scholar
• Zou W, Zou Y, Zhao Z, et al. Nicotine-induced epithelial-mesenchymal transition via Wnt/β-catenin signaling in human airway epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2013 Feb 15;304(4):L199–209.
   PubMed Web of Science ®Google Scholar
• Carlier FM, Dupasquier S, Ambroise J, et al. Canonical WNT pathway is activated in the airway epithelium in chronic obstructive pulmonary disease. EBioMedicine. 2020 Nov;61:103034.
   PubMed Web of Science ®Google Scholar